"The data in this Phase 2 trial continue to strengthen as we have added patients," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We believe that tanespimycin is highly active in patients with HER2-positive metastatic breast cancer who have progressed on trastuzumab, and that this drug candidate's overall profile is attractive. We intend to complete this Phase 2 trial and embark upon next steps to explore tanespimycin's therapeutic potential in breast cancer."
Phase 2 Tanespimycin Data
Tanespimycin is an Hsp90 inhibitor that has demonstrated the potential to disrupt the activity of multiple oncogenes and cell signaling pathways implicated in tumor growth, including HER2, a key pathway in breast cancer.
The objective of the Phase 2 trial is to determine the objective
response rate by RECIST in patients with HER2-positive metastatic breast
cancer. To be eligible for the trial, patients may have had either
progressive disease within 3 months following last dose of adjuvant
treatment with trastuzumab or have progressive disease following initial
therapy for metastatic disease with trastuzumab (trastuzumab may have been
administered with cytotoxic chemotherapy or as a single agent). All but one
patient received trastuzumab in the metastatic setting (one patient
received trastuzumab only in the adjuvant setting). Tanespimycin was
administered at a dose of 450 mg/m2 foll
|SOURCE Kosan Biosciences Incorporated|
Copyright©2007 PR Newswire.
All rights reserved